121 related articles for article (PubMed ID: 11786751)
21. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
[TBL] [Abstract][Full Text] [Related]
22. Interim 18F-FDG PET in Hodgkin lymphoma: would PET-adapted clinical trials lead to a paradigm shift?
Kostakoglu L; Gallamini A
J Nucl Med; 2013 Jul; 54(7):1082-93. PubMed ID: 23818548
[TBL] [Abstract][Full Text] [Related]
23. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity?
Spaepen K; Stroobants S; Dupont P; Thomas J; Vandenberghe P; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G
Br J Haematol; 2001 Nov; 115(2):272-8. PubMed ID: 11703321
[TBL] [Abstract][Full Text] [Related]
24. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.
Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A
Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777
[TBL] [Abstract][Full Text] [Related]
25. Fluorine-18 fluorodeoxyglucose splenic uptake from extramedullary hematopoiesis after granulocyte colony-stimulating factor stimulation.
Abdel-Dayem HM; Rosen G; El-Zeftawy H; Naddaf S; Kumar M; Atay S; Cacavio A
Clin Nucl Med; 1999 May; 24(5):319-22. PubMed ID: 10232468
[TBL] [Abstract][Full Text] [Related]
26. Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care.
Kaplan LD
Am J Med; 2002 Mar; 112(4):320-1. PubMed ID: 11893374
[No Abstract] [Full Text] [Related]
27. FDG positron emission tomography in lymphoma.
Tecnologica MAP Suppl; 2000 Jan; ():9-10. PubMed ID: 10848116
[No Abstract] [Full Text] [Related]
28. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients.
Girinsky T; Aupérin A; Ribrag V; Elleuch M; Fermé C; Bonniaud G; Ruelle C; Alberini JL; Celebic A; Edeline V
Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1047-1052. PubMed ID: 25035208
[TBL] [Abstract][Full Text] [Related]
29. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging.
Hollinger EF; Alibazoglu H; Ali A; Green A; Lamonica G
Clin Nucl Med; 1998 Feb; 23(2):93-8. PubMed ID: 9481497
[TBL] [Abstract][Full Text] [Related]
30. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
[TBL] [Abstract][Full Text] [Related]
31. False-negative interpretation of FDG positron emission tomography in a patient with Hodgkin's lymphoma.
Kim W; Yun M; Alnafisi N; Hickeson M; Alavi A
Clin Nucl Med; 2002 May; 27(5):367-8. PubMed ID: 11953577
[No Abstract] [Full Text] [Related]
32. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
33. Unusually elevated liver radioactivity on F-18 FDG PET in Hodgkin's disease: hepatic 'superscan'.
Basu S; Nair N
Clin Nucl Med; 2004 Oct; 29(10):626-8. PubMed ID: 15365434
[TBL] [Abstract][Full Text] [Related]
34. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment].
Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L
Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Importance of Bone Marrow Uptake on Baseline
Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
[TBL] [Abstract][Full Text] [Related]
36. PET imaging in pediatric Hodgkin's lymphoma.
Hudson MM; Krasin MJ; Kaste SC
Pediatr Radiol; 2004 Mar; 34(3):190-8. PubMed ID: 14745528
[TBL] [Abstract][Full Text] [Related]
37. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
[TBL] [Abstract][Full Text] [Related]
38. Similar pelvic abnormalities on FDG positron emission tomography of different origins.
Zhuang H; Yamamoto AJ; Sinha P; Pourdehnad M; Liu Y; Alavi A
Clin Nucl Med; 2001 Jun; 26(6):515-7. PubMed ID: 11353298
[TBL] [Abstract][Full Text] [Related]
39. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients.
Spaepen K; Stroobants S; Verhoef G; Mortelmans L
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S97-105. PubMed ID: 12709831
[TBL] [Abstract][Full Text] [Related]
40. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
